After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway. Today, the FDA approved CSL’s garadacimab-gxii ...
Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...
SAN ANTONIO -- Among patients with hereditary angioedema (HAE), monthly injections of the investigational biologic garadacimab reduced the mean attack rate substantially in the phase III VANGUARD ...
Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think there's a huge unmet need ...
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results